How should digoxin be administered to the pregnant mother for fetal tachycardia with a fetal heart rate of 180 beats per minute?

Digoxin Administration for Fetal Tachycardia (HR 180 bpm)

For fetal tachycardia at 180 bpm, initiate maternal oral digoxin at 0.25 mg daily (or 0.5 mg every 12 hours if more aggressive treatment needed), with close monitoring of maternal digoxin levels to maintain 0.8-2.0 ng/mL, recognizing that digoxin alone has only 32-50% success rate and flecainide will likely need to be added if conversion doesn't occur within 4-7 days. 1, 2

Initial Assessment

Before starting treatment, determine:

• Fetal hydrops status - presence dramatically reduces digoxin efficacy and increases mortality risk
• Tachycardia mechanism - short VA interval (80% of cases) vs long VA interval via fetal echocardiography
• Gestational age - must be <35 weeks for transplacental treatment
• Maternal contraindications - renal function, baseline ECG, electrolytes

Digoxin Dosing Protocol

For Non-Hydropic Fetuses (Better Prognosis)

Oral regimen (preferred for HR 180 bpm):

• Start with 0.25 mg daily in women under 70 with normal renal function 3
• Alternative loading: 0.5 mg every 8 hours for 24 hours, then 0.5 mg every 12 hours for maintenance 4
• Target maternal digoxin level: 0.8-2.0 ng/mL (levels >2 ng/mL cause maternal side effects) 5

Intravenous regimen (if more aggressive approach needed):

• Loading: 1-2 mg IV over first 24 hours in divided doses 6
• Continue IV for at least 5-7 days before converting to oral 7, 6
• This approach showed better success in prospective studies

For Hydropic Fetuses (Poor Prognosis with Digoxin Alone)

Skip digoxin monotherapy and proceed directly to combination therapy - digoxin alone has only 38% success rate in hydrops vs 86-100% with flecainide 2. Maternal mortality in hydropic fetuses treated with digoxin alone was 43% vs 0% with flecainide 2.

Expected Response Timeline

• Conversion typically occurs within 4-5 days (median 4.5 days, IQR 3-6.5) if digoxin will work 1
• If no conversion by day 7, add flecainide rather than continuing digoxin alone
• Overall digoxin monotherapy success: 32-50% for short VA tachycardia 1, 2

When to Add Flecainide

Add flecainide 300 mg daily (divided doses) if:

• No conversion after 5-7 days of digoxin
• Hydrops is present (consider starting combination therapy immediately)
• Fetal condition deteriorating

This increases success rate to 93-96% 1, 2

Monitoring Requirements

Maternal monitoring:

• Digoxin levels every 3-5 days initially, then weekly
• ECG for PR interval prolongation, ST depression (expected findings, not toxicity) 3
• Watch for nausea (most common side effect when levels >2 ng/mL) 5
• Electrolytes, especially potassium (hypokalemia increases toxicity risk) 3

Fetal monitoring:

• Serial echocardiography every 2-3 days to assess heart rate and cardiac function
• Fetal/maternal digoxin ratio approximately 0.45-0.51 1

Critical Pitfalls to Avoid

1. Don't use oral digoxin alone in hydropic fetuses - mortality risk is unacceptably high 2
2. Don't wait too long to add flecainide - if no response by day 7, escalate therapy
3. Don't ignore maternal side effects - reduce dose if digoxin level >2 ng/mL even if fetus hasn't converted 5
4. Don't use atenolol - contraindicated in pregnancy for arrhythmias 8
5. Pregnancy increases digoxin clearance - higher doses may be needed than in non-pregnant patients (clearance 16-19 L/h vs typical 12 L/h) 4

Special Considerations for HR 180 bpm

At 180 bpm, this represents borderline sustained tachycardia (threshold is >180 bpm). However, treatment is still indicated if:

• Tachycardia is sustained (not intermittent runs)
• Any signs of cardiac compromise or hydrops
• Gestational age allows time for transplacental therapy

The ESC guidelines recommend digoxin or metoprolol as first-line for long-term SVT management 8, but the evidence strongly favors starting with digoxin given the extensive experience in fetal tachycardia treatment.

Algorithm Summary

1. Confirm sustained tachycardia + assess for hydrops
2. No hydrops: Start oral digoxin 0.25-0.5 mg daily or IV protocol
3. Hydrops present: Consider flecainide ± digoxin from start
4. Monitor response at 5-7 days
5. No conversion: Add flecainide 300 mg daily
6. Target maternal digoxin 0.8-2.0 ng/mL throughout